Skip to main navigation
logo

Investor Navigation

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
  • Governance
    • Documents & Charters
    • Board of Directors
    • Executive Team
    • Committee Composition
  • IR Resources
    • Investor FAQ
    • Contact IR
    • Email Alerts

Press Releases

31 Jan '2023
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
09 Jan '2023
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
04 Jan '2023
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 13 of 13

Investor Tools

  • Print Page
  • RSS Feeds
  • Search

© 2023 Context Therapeutics Inc.     All rights reserved.